MIR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2, and Src

Xu Bao Shi, Ai Hong Ma, Lingru Xue, Meimei Li, Hao G. Nguyen, Joy C. Yang, Clifford G Tepper, Regina F Gandour-Edwards, Christopher P Evans, Hsing-Jien Kung, Ralph W deVere White

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

miR-124 targets the androgen receptor (AR) transcript, acting as a tumor suppressor to broadly limit the growth of prostate cancer. In this study, we unraveled the mechanisms through which miR-124 acts in this setting. miR-124 inhibited proliferation of prostate cancer cells in vitro and sensitized them to inhibitors of androgen receptor signaling. Notably, miR-124 could restore the apoptotic response of cells resistant to enzalutamide, a drug approved for the treatment of castration-resistant prostate cancer. We used xenograft models to examine the effects of miR-124 in vivo when complexed with polyethylenimine-derived nanoparticles. Intravenous delivery of miR-124 was sufficient to inhibit tumor growth and to increase tumor cell apoptosis in combination with enzalutamide. Mechanistic investigations revealed that miR-124 directly downregulated AR splice variants AR-V4 and V7 along with EZH2 and Src, oncogenic targets that have been reported to contribute to prostate cancer progression and treatment resistance. Taken together, our results offer a preclinical rationale to evaluate miR-124 for cancer treatment.

Original languageEnglish (US)
Pages (from-to)5309-5317
Number of pages9
JournalCancer Research
Volume75
Issue number24
DOIs
StatePublished - Dec 15 2015

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Down-Regulation
Growth
Neoplasms
Polyethyleneimine
Castration
Heterografts
Nanoparticles
Apoptosis
Pharmaceutical Preparations
MDV 3100

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

MIR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2, and Src. / Shi, Xu Bao; Ma, Ai Hong; Xue, Lingru; Li, Meimei; Nguyen, Hao G.; Yang, Joy C.; Tepper, Clifford G; Gandour-Edwards, Regina F; Evans, Christopher P; Kung, Hsing-Jien; deVere White, Ralph W.

In: Cancer Research, Vol. 75, No. 24, 15.12.2015, p. 5309-5317.

Research output: Contribution to journalArticle

@article{be77df5b71f04f33951ad6fcefb6f4c1,
title = "MIR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2, and Src",
abstract = "miR-124 targets the androgen receptor (AR) transcript, acting as a tumor suppressor to broadly limit the growth of prostate cancer. In this study, we unraveled the mechanisms through which miR-124 acts in this setting. miR-124 inhibited proliferation of prostate cancer cells in vitro and sensitized them to inhibitors of androgen receptor signaling. Notably, miR-124 could restore the apoptotic response of cells resistant to enzalutamide, a drug approved for the treatment of castration-resistant prostate cancer. We used xenograft models to examine the effects of miR-124 in vivo when complexed with polyethylenimine-derived nanoparticles. Intravenous delivery of miR-124 was sufficient to inhibit tumor growth and to increase tumor cell apoptosis in combination with enzalutamide. Mechanistic investigations revealed that miR-124 directly downregulated AR splice variants AR-V4 and V7 along with EZH2 and Src, oncogenic targets that have been reported to contribute to prostate cancer progression and treatment resistance. Taken together, our results offer a preclinical rationale to evaluate miR-124 for cancer treatment.",
author = "Shi, {Xu Bao} and Ma, {Ai Hong} and Lingru Xue and Meimei Li and Nguyen, {Hao G.} and Yang, {Joy C.} and Tepper, {Clifford G} and Gandour-Edwards, {Regina F} and Evans, {Christopher P} and Hsing-Jien Kung and {deVere White}, {Ralph W}",
year = "2015",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-14-0795",
language = "English (US)",
volume = "75",
pages = "5309--5317",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - MIR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2, and Src

AU - Shi, Xu Bao

AU - Ma, Ai Hong

AU - Xue, Lingru

AU - Li, Meimei

AU - Nguyen, Hao G.

AU - Yang, Joy C.

AU - Tepper, Clifford G

AU - Gandour-Edwards, Regina F

AU - Evans, Christopher P

AU - Kung, Hsing-Jien

AU - deVere White, Ralph W

PY - 2015/12/15

Y1 - 2015/12/15

N2 - miR-124 targets the androgen receptor (AR) transcript, acting as a tumor suppressor to broadly limit the growth of prostate cancer. In this study, we unraveled the mechanisms through which miR-124 acts in this setting. miR-124 inhibited proliferation of prostate cancer cells in vitro and sensitized them to inhibitors of androgen receptor signaling. Notably, miR-124 could restore the apoptotic response of cells resistant to enzalutamide, a drug approved for the treatment of castration-resistant prostate cancer. We used xenograft models to examine the effects of miR-124 in vivo when complexed with polyethylenimine-derived nanoparticles. Intravenous delivery of miR-124 was sufficient to inhibit tumor growth and to increase tumor cell apoptosis in combination with enzalutamide. Mechanistic investigations revealed that miR-124 directly downregulated AR splice variants AR-V4 and V7 along with EZH2 and Src, oncogenic targets that have been reported to contribute to prostate cancer progression and treatment resistance. Taken together, our results offer a preclinical rationale to evaluate miR-124 for cancer treatment.

AB - miR-124 targets the androgen receptor (AR) transcript, acting as a tumor suppressor to broadly limit the growth of prostate cancer. In this study, we unraveled the mechanisms through which miR-124 acts in this setting. miR-124 inhibited proliferation of prostate cancer cells in vitro and sensitized them to inhibitors of androgen receptor signaling. Notably, miR-124 could restore the apoptotic response of cells resistant to enzalutamide, a drug approved for the treatment of castration-resistant prostate cancer. We used xenograft models to examine the effects of miR-124 in vivo when complexed with polyethylenimine-derived nanoparticles. Intravenous delivery of miR-124 was sufficient to inhibit tumor growth and to increase tumor cell apoptosis in combination with enzalutamide. Mechanistic investigations revealed that miR-124 directly downregulated AR splice variants AR-V4 and V7 along with EZH2 and Src, oncogenic targets that have been reported to contribute to prostate cancer progression and treatment resistance. Taken together, our results offer a preclinical rationale to evaluate miR-124 for cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=84955496300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955496300&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-0795

DO - 10.1158/0008-5472.CAN-14-0795

M3 - Article

C2 - 26573802

AN - SCOPUS:84955496300

VL - 75

SP - 5309

EP - 5317

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 24

ER -